<?xml version="1.0" encoding="UTF-8"?>
<p>Type I interferons (IFN), especially IFN-beta, have been proposed as potential cornerstone therapies to address severe COVID-19 and are currently assessed in REMAP-CAP and the WHOâ€™s Solidarity Trial [
 <xref rid="B151-jcm-09-02084" ref-type="bibr">151</xref>]. An important perspective consists of the fact that COVID-19 pathology induces an excessive IFN-I mediated antiviral response, leading to tissue damage. Therefore, IFN-I treatment should be limited to the early phases of the infection if this hypothesis is confirmed, as shown by previous studies [
 <xref rid="B152-jcm-09-02084" ref-type="bibr">152</xref>] and by early clinical data suggesting a link between inflammatory biomarkers and increased mortality [
 <xref rid="B153-jcm-09-02084" ref-type="bibr">153</xref>].
</p>
